Quantitation of Membrane Type Serine Protease 1 (MT-SP1) in Transformed and Normal Cells
- 20 January 2003
- journal article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 384 (2) , 257-66
- https://doi.org/10.1515/bc.2003.029
Abstract
Membrane type serine protease 1 (MT-SP1) is a representative member of a large family of related enzymes known as type II transmembrane serine proteases or membrane type serine proteases. MT-SP1 has been implicated in the selective proteolysis of key extracellular substrates but its physiological role is still not fully understood. MT-SP1 expression at the protein and RNA level has been previously examined by nonquantitative methods such as in situ hybridization, Northern blotting and immunohistochemistry. To establish an introductory understanding of the quantitative mRNA expression of MT-SP1 and to correlate these levels with urokinase-type plasminogen activator receptor (uPAR), a key component of extracellular proteolysis, quantitative RT-PCR was carried out. RNA expression was analyzed in 34 human cancer cell lines, 26 human tissues and 18 primary human breast cancer tissue samples. MT-SP1 mRNA is highly expressed in many breast, ovarian, prostate and colon cancer cell lines and normal human tissues of endodermal origin. At the transcript level, MT-SP1 shows a highly statistically significant correlation (Pearson's product moment correlation r = 0.784, p < 0.001) with uPAR in human breast cancer tissue. The exact role of MT-SP1 in concert with proteins such as uPAR and other members of the plasminogen activator cascade has yet to be ascertained. However, the significant correlation between MT-SP1 and uPAR transcript levels in this initial study suggests further work to establish the role of MT-SP1 as a possible prognostic, diagnostic or therapeutic target for breast cancer.Keywords
This publication has 28 references indexed in Scilit:
- Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in CombinationJournal of Clinical Oncology, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumoursBritish Journal of Cancer, 2001
- Type II Transmembrane Serine ProteasesJournal of Biological Chemistry, 2001
- Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine ProteaseJournal of Biological Chemistry, 2000
- The Hallmarks of CancerCell, 2000
- Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre studyBritish Journal of Cancer, 1999
- The Fibrinolytic System in NeoplasiaSeminars in Thrombosis and Hemostasis, 1996
- Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissuesBreast Cancer Research and Treatment, 1996
- Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancersJournal of Cellular Biochemistry, 1993